FDG-PET in T-cell and NK-cell neoplasms

Ann Oncol. 2007 Oct;18(10):1685-90. doi: 10.1093/annonc/mdm265. Epub 2007 Aug 22.

Abstract

Background: A growing number of studies demonstrate the utility of (18)fluoro-2-deoxyglucose positron emission tomography (FDG-PET) in the management of malignant lymphoma. The results of FDG-PET, however, have not been studied extensively for T-cell and natural killer (NK)-cell neoplasms.

Patients and methods: We retrospectively evaluated pretreatment FDG-PET scans in 41 patients with T/NK-cell neoplasms diagnosed according to the World Health Organization (WHO) classification. Histological subtypes frequently included were peripheral T-cell lymphoma, unspecified (PTCLu, n = 11), extranodal NK/T-cell lymphoma, nasal type (ENKL, n = 8), primary cutaneous anaplastic large cell lymphoma (C-ALCL, n = 5), and angioimmunoblastic T-cell lymphoma (AILT, n = 4).

Results: FDG-PET detected a lymphoma lesion in at least one site in 36 out of 41 patients. The positive rate was equally high in most histological subtypes except for cutaneous lymphomas: PTCLu 91%, ENKL 100%, C-ALCL 60%, AILT 100%. All the patients without an FDG-avid lesion had lesions restricted to skin. Among patients who had cutaneous lesions, only 50% had FDG-avid cutaneous lesions, all of which were tumorous. The positive rate of FDG-PET for bone marrow involvement was only 20%.

Conclusion: T/NK-cell neoplasms incorporated in this study were generally FDG-avid except for cutaneous lesions and bone marrow involvement.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Bone Marrow / pathology*
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Killer Cells, Natural / pathology*
  • Lymphoma, Primary Cutaneous Anaplastic Large Cell / diagnostic imaging*
  • Lymphoma, T-Cell / diagnostic imaging*
  • Lymphoma, T-Cell / pathology
  • Male
  • Middle Aged
  • Positron-Emission Tomography / methods*
  • Retrospective Studies

Substances

  • Fluorodeoxyglucose F18